Company profile: Pinteon Therapeutics
1.1 - Company Overview
Company description
- Provider of a monoclonal antibody therapeutic, PNT001, targeting cis-pT231 tau to reduce neurodegeneration and cognitive impairment in traumatic brain injury, chronic traumatic encephalopathy, Alzheimer's disease, and progressive supranuclear palsy; advancing clinical studies of this novel antibody.
Products and services
- PNT001: Monoclonal antibody targeting cis-pT231 tau protein, aimed at reducing neurodegeneration and cognitive impairment specifically in Alzheimer's disease
- PNT001: Monoclonal antibody targeting cis-pT231 tau protein, aimed at reducing neurodegeneration and cognitive impairment in progressive supranuclear palsy
- PNT001: Monoclonal antibody targeting cis-pT231 tau protein, aimed at reducing neurodegeneration and cognitive impairment in traumatic brain injury and chronic traumatic encephalopathy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pinteon Therapeutics
Propagenix
HQ: United States
Website
- Description: Provider of healthcare technology platforms for translational biomedical research, including EpiX technology to expand primary epithelial cells without genetic modification, CR feeder-cell culture to replicate epithelial cells, engineered bi-layered skin constructs, airway epithelium models and theranostic assays, and collaborative and sponsored research for drug discovery and toxicology screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propagenix company profile →
CohBar
HQ: United States
Website
- Description: Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CohBar company profile →
Arena Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, central nervous system, inflammatory, and metabolic diseases, including the development of lorcaserin hydrochloride, which has reported positive clinical trial data. Headquartered in San Diego, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arena Pharmaceuticals company profile →
Vertex Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs for serious diseases, including cystic fibrosis medicines, and research and development of therapies for sickle cell disease, type 1 diabetes, APOL1-mediated kidney disease, pain management, and beta thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vertex Pharmaceuticals company profile →
Regeneron
HQ: United States
Website
- Description: Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regeneron company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pinteon Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pinteon Therapeutics
2.2 - Growth funds investing in similar companies to Pinteon Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pinteon Therapeutics
4.2 - Public trading comparable groups for Pinteon Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →